Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NL-OMON52141
NL-OMON52141RecruitingPhase 4

Efficacy, safety and cost-effectiveness of B cell tailored ocrelizumab versus standard ocrelizumab in relapsing remitting multiple sclerosis: a randomized controlled trial - BLOOMS trial

Vrije Universiteit Medisch Centrum0 sites296 target enrollmentStarted: TBDLast updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Phase 4
Status
Recruiting
Enrollment
296
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
18 to 64 (—)

Inclusion Criteria

  • •multiple sclerosis
  • •minimally 48 weeks of treatment with ocrelizumab

Exclusion Criteria

  • •age below 18
  • •inability to undergo frequent MRIs

Investigators

Similar Trials

Active, not recruiting
Phase 1
Personalized dosing of ocrelizumab in MSMultiple sclerosis
EUCTR2021-004791-34-NLVU medical center296
Active, not recruiting
Phase 4
B Cell Tailored Ocrelizumab Versus Standard Ocrelizumab in Relapsing Remitting Multiple SclerosisMultiple Sclerosis, Relapsing-Remitting
NCT05296161Amsterdam UMC, location VUmc296
Not yet recruiting
Not Applicable
Effectiveness and safety of low dose Rituximab in primary membranous nephropathy
CTRI/2020/12/029849il
Active, not recruiting
Not Applicable
Evaluation of the immune response and safety of a booster dose of Pfizer's13-valent pneumococcal conjugate vaccine in children primed with 2 dosesof either GSK's 10-valent pneumococcal conjugate vaccine or Pfizer's 13-valent pneumococcal conjugate vaccine in the Slovak RepublicTo induce appropriate protection against pneumococcal disease. Toassess non-inferiority of OPA response for serotype 19A after boosterdose of PCV13 administered between 11-12 months of age in subjectsprimed with 10Pn-PD-DiT vs those primed with PCV13.
EUCTR2012-005367-27-SKBIOVOMED
Active, not recruiting
Not Applicable
Evaluation of the immune response and safety of a booster dose of Pfizer’s 13-valent pneumococcal conjugate vaccine in children primed with 3 doses of either GSK’s 10-valent pneumococcal conjugate vaccine or Pfizer’s 13-valent pneumococcal conjugate vaccine in the Czech Republic.To induce appropriate protection against pneumococcal disease. To assess non-inferiority of OPA response for serotype 19A after booster dose of PCV13 administered between 12-15 months of age in subjects primed with 10Pn-PD-DiT vs those primed with PCV13.
EUCTR2012-005366-35-CZBIOVOMED